15 resultados para Genotoxicity test

em Institute of Public Health in Ireland, Ireland


Relevância:

20.00% 20.00%

Publicador:

Resumo:

2007 Sight Test Survey Report

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This leaflet is used to support the Northern Ireland breast screening programme and is issued to the one in 20 women who are called back after their initial breast x-ray for further tests at a breast assessment clinic

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Format: 6 page A5 leaflet Target group: Prospective participants in the Northern Ireland Bowel cancer screening programme Description: This leaflet provides step by step instructions on using the Faecal Occult Blood test (FOBt) for bowel cancer screening.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Format: 6 page A5 leaflet Target group: Participants in the Northern Ireland Bowel cancer screening programme who require a second test. Description: This leaflet provides step by step instructions on using the Faecal Immunochemical Test (FIT) for bowel cancer screening.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

From January 2011, the Northern Ireland cervical screening programme no longer invited women aged under 25 to attend for screening. In addition, the screening interval for women aged 25-49 was reduced to every three years. This leaflet is one of a series of new information materials that was developed to reflect the policy changes and to give information to increase the uptake of information and interventions offered to protect and maintain the health of women in the target group. It gives information about cervical screening in Northern Ireland and helps women to understand why it is important to be screened.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This poster highlights the bowel cancer screening programme is being introduced for all 60 to 71 year olds. If you are in this age group a kit will be sent by post so you can do the test at home. You are encouraged to look out for the kit as it could save your life.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This poster highlights the bowel cancer screening programme is being introduced for all 60 to 71 year olds. If you are in this age group a kit will be sent by post so you can do the test at home. You are encouraged to look out for the kit as it could save your life.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This poster highlights the importance of taking the bowel cancer screening test which will be posted out to you if you are aged 60-71 years old. You are encouraged to look out for the kit as it could save your life.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively.The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years.The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. This flowchart poster outlines the new triage and test of cure process. It was distributed to all GPs in Northern Ireland and is available to download as a PDF from this website.�

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This poster highlights the bowel cancer screening programme is being introduced for all 60 to 74 year olds. If you are in this age group a kit will be sent by post so you can do the test at home. You are encouraged to look out for the kit as it could save your life.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This leaflet provides step-by-step instructions on using the Faecal Immunochemical�Test (FIT) for bowel cancer screening. This kit is slightly different to the one we usually use as part of Northern Ireland��'s bowel cancer screening programme. It is easier to complete for people who are partially sighted and is sent following discussion with the screening helpline team.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This leaflet provides step by step instructions on using the Faecal Occult Blood test (FOBt) for bowel cancer screening.The translations are of the 2010 versions when screening was for 60��-69 year olds but this has been extended to 60��-74 year olds.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This leaflet provides step by step instructions on using the Faecal Immunochemical Test (FIT) for bowel cancer screening.The translations are of the 2010 versions when screening was for 60��-69 year olds but this has been extended to 60��-74 year olds.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result.